In this review:
Pembrolizumab vs platinum-based chemotherapy
Durvalumab in locally advanced, unresectable NSCLC
SABR vs conventional radiotherapy for inoperable stage 1 NSCLC
Lorlatinib in patients with advanced ALK+ NSCLC
Early specialist palliative care in malignant pleural mesothelioma
Prophylactic irradiation of tracts in malignant pleural mesothelioma
Current status of smoking cessation
PD-L1 immunohistochemistry
Osimertinib in EGFR mutant advanced NSCLC
Lung cancer perceived risk, screening eligibility and worry
Please login below to download this issue (PDF)